Coming Soon: Revolutionizing Lung Cancer Detection

Harness the power of the CIZ1B biomarker for early-stage detection.

The Urgent Need for Early Detection

Global Impact of Lung Cancer

0 million

Annual Diagnoses:

Over 2.2 million individuals are diagnosed with lung cancer each year globally.

0%

Mortality and Prevalence:

In 2020, cancer claimed 10 million lives worldwide, with lung cancer accounting for nearly 20% of these fatalities — more than any other cancer.

0%

Late-Stage Diagnosis:

Approximately 75% of lung cancer cases are diagnosed at a late stage, drastically reducing survival rates and emphasizing the need for early detection.

    Less than:
    0%
    Are caught in early stages
  

Promise of Early Detection:

Survival Rates:

The survival rate for lung cancer increases dramatically when diagnosed early. However, less than 20% of cases are caught in these early stages.

0%

Screening Rates:

Only 5.8% of the eligible 14.2 million people have been screened for lung cancer as of 2021, pointing to a significant gap in preventive healthcare.

Our Goal

Cizzle Bio, Inc. aims to bridge this gap with pioneering diagnostic tools that enable early detection, potentially saving millions of lives.

Cizzle Bio, Inc. is licensed exclusively in the USA and Canada, and is poised to transform lung cancer detection with simple blood tests capable of identifying the CIZ1B biomarker in its early stages.

Join us in the fight against lung cancer.

Help us change these dire statistics. Stay informed and support advancements in lung cancer diagnostics. Subscribe for updates. Enter your email addresses to receive news about the launch and developments.